Retour

Arcutis to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024

Calendar Calendar of Events

Arcutis today announced that it will report first quarter 2024 financial results and provide a business update on Tuesday, May 14, 2024.

GlobeNewswire Inc. • 29/04/2024 à 22:00:00
Arcutis Biotherapeutics, Inc. Common Stock
Address: 3027 TOWNSGATE ROAD
Postal Code: 91361
City: WESTLAKE VILLAGE
State: CA
Phone Number: 805-418-5006
Website: https://www.arcutis.com
Status: Active
Company Info

Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.

List Date2020-01-31
MarketStocks
LocalUS
Primary ExchangeXNAS
TypeCS
Currency NameUSD
CIK0001787306
Composite figiBBG00QN8K4M4
Share Class figiBBG00QN8K4P1
Market Cap905,715,914 USD
SIC Code2834
SIC DescriptionPHARMACEUTICAL PREPARATIONS
Total Employees296
Share Class Shares Outstanding115530000
Weighted Shares Outstanding115524989
Round Lot100
Updated date2024-05-12
Stats
Last 5 days
15-05
14-05
13-05
10-05
9-05
Last
9.116
9.77
7.94
7.945
7.841
Variance
-6.89%
23.05%
-0.13%
0.79%
-1.74%
Open
9.791
7.94
7.95
7.883
7.98
Highest
10.673
11.065
8.174
8.486
8.295
Lowest
10.55
10.682
8.105
8.466
8.288
History
PeriodVarhighestlowest
1 week
10.78%
8.295
8.105
1 month
-11.02%
10.317
7.995
3 month
-3.97%
9.532
7.995
6 month
316.98%
2.13
1.76
1 year
-13.33%
10.27
1.76
3 year
-65.43%
25.68
1.76
5 year
-61.65%
24.4
1.76
10 year
-61.65%
24.4
1.76
Stock Financials
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-09 2023-08-08 2023-11-03 UNPUB
Assets 379,458,000 320,689,000 292,959,000 UNPUB
Current Assets 367,676,000 308,868,000 281,548,000 UNPUB
Current Liabilities 37,025,000 36,659,000 41,889,000 UNPUB
Equity 139,732,000 80,508,000 46,717,000 UNPUB
Equity Attributable To Noncontrolling Interest 0 0 0 UNPUB
Equity Attributable To Parent 139,732,000 80,508,000 46,717,000 UNPUB
Liabilities 239,726,000 240,181,000 246,242,000 UNPUB
Liabilities And Equity 379,458,000 320,689,000 292,959,000 UNPUB
Noncurrent Assets 11,782,000 11,821,000 11,411,000 UNPUB
Noncurrent Liabilities 202,701,000 203,522,000 204,353,000 UNPUB
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-09 2023-08-08 2023-11-03 UNPUB
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow 27,507,000 23,700,000 2,432,000 UNPUB
Net Cash Flow, Continuing 27,507,000 23,700,000 2,432,000 UNPUB
Net Cash Flow From Financing Activities 100,000 1,067,000 867,000 UNPUB
Net Cash Flow From Financing Activities, Continuing 100,000 1,067,000 867,000 UNPUB
Net Cash Flow From Investing Activities 107,751,000 89,118,000 45,549,000 UNPUB
Net Cash Flow From Investing Activities, Continuing 107,751,000 89,118,000 45,549,000 UNPUB
Net Cash Flow From Operating Activities -80,344,000 -66,485,000 -43,984,000 UNPUB
Net Cash Flow From Operating Activities, Continuing -80,344,000 -66,485,000 -43,984,000 UNPUB
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-09 2023-08-08 2023-11-03 UNPUB
Comprehensive Income/Loss -79,428,000 -70,869,000 -44,657,000 UNPUB
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 UNPUB
Comprehensive Income/Loss Attributable To Parent -79,428,000 -70,869,000 -44,657,000 UNPUB
Other Comprehensive Income/Loss -79,428,000 -70,869,000 -44,657,000 UNPUB
Other Comprehensive Income/Loss Attributable To Parent 672,000 122,000 108,000 UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-09 2023-08-08 2023-11-03 UNPUB
Basic Earnings Per Share -1 -1 -1 UNPUB
Benefits Costs and Expenses 0 0 0 UNPUB
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses 79,046,000 71,953,000 75,013,000 UNPUB
Diluted Earnings Per Share -1 -1 -1 UNPUB
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -80,100,000 -70,991,000 -44,765,000 UNPUB
Income/Loss From Continuing Operations Before Tax 2,781,000 5,190,000 38,109,000 UNPUB
Income Tax Expense/Benefit UNPUB UNPUB 3,023,000 UNPUB
Interest Expense, Operating 7,042,000 7,349,000 7,559,000 UNPUB
Net Income/Loss -80,100,000 -70,991,000 -44,765,000 UNPUB
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 UNPUB
Net Income/Loss Attributable To Parent -80,100,000 -70,991,000 -44,765,000 UNPUB
Net Income/Loss Available To Common Stockholders, Basic -80,100,000 -70,991,000 -44,765,000 UNPUB
Operating Expenses 79,046,000 71,953,000 75,013,000 UNPUB
Operating Income/Loss -76,265,000 -66,763,000 -36,904,000 UNPUB
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 UNPUB
Preferred Stock Dividends And Other Adjustments 0 0 0 UNPUB
Revenues 2,781,000 5,190,000 38,109,000 UNPUB
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB 2022-08-04 2022-11-08 2023-02-28
Assets UNPUB 300,464,000 508,914,000 449,274,000
Current Assets UNPUB 295,426,000 496,719,000 437,406,000
Current Liabilities UNPUB 27,482,000 37,102,000 37,807,000
Equity UNPUB 195,382,000 270,774,000 209,581,000
Equity Attributable To Noncontrolling Interest UNPUB 0 0 0
Equity Attributable To Parent UNPUB 195,382,000 270,774,000 209,581,000
Liabilities UNPUB 105,082,000 238,140,000 239,693,000
Liabilities And Equity UNPUB 300,464,000 508,914,000 449,274,000
Noncurrent Assets UNPUB 5,038,000 12,195,000 11,868,000
Noncurrent Liabilities UNPUB 0 201,038,000 201,886,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB 2022-08-04 2022-11-08 2023-02-28
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow UNPUB UNPUB 20,032,000 -43,116,000
Net Cash Flow, Continuing UNPUB UNPUB 20,032,000 -43,116,000
Net Cash Flow From Financing Activities UNPUB UNPUB 284,989,000 301,798,000
Net Cash Flow From Financing Activities, Continuing UNPUB UNPUB 284,989,000 301,798,000
Net Cash Flow From Investing Activities UNPUB UNPUB -197,262,000 -87,199,000
Net Cash Flow From Investing Activities, Continuing UNPUB UNPUB -197,262,000 -87,199,000
Net Cash Flow From Operating Activities UNPUB UNPUB -67,695,000 -257,715,000
Net Cash Flow From Operating Activities, Continuing UNPUB UNPUB -67,695,000 -257,715,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB 2022-08-04 2022-11-08 2023-02-28
Comprehensive Income/Loss UNPUB -67,406,000 -108,053,000 -312,289,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest UNPUB 0 0 0
Comprehensive Income/Loss Attributable To Parent UNPUB -67,638,000 -108,053,000 -312,289,000
Other Comprehensive Income/Loss UNPUB 0 -108,053,000 -312,289,000
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB 2022-08-04 2022-11-08 2023-02-28
Basic Earnings Per Share UNPUB -1 -2 -6
Benefits Costs and Expenses UNPUB UNPUB 0 0
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses UNPUB UNPUB 105,473,000 305,313,000
Diluted Earnings Per Share UNPUB -1 -2 -6
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax UNPUB -67,406,000 -107,709,000 -311,458,000
Income/Loss From Continuing Operations Before Tax UNPUB -67,406,000 725,000 3,686,000
Income Tax Expense/Benefit UNPUB UNPUB UNPUB 0
Interest Expense, Operating UNPUB 2,000,000 4,899,000 15,652,000
Net Income/Loss UNPUB -67,406,000 -107,709,000 -311,458,000
Net Income/Loss Attributable To Noncontrolling Interest UNPUB 0 0 0
Net Income/Loss Attributable To Parent UNPUB -67,406,000 -107,709,000 -311,458,000
Net Income/Loss Available To Common Stockholders, Basic UNPUB -67,406,000 -107,709,000 -311,458,000
Operating Expenses UNPUB 65,827,000 105,473,000 305,313,000
Operating Income/Loss UNPUB -65,827,000 -104,748,000 -301,627,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic UNPUB 0 0 0
Preferred Stock Dividends And Other Adjustments UNPUB 0 0 0
Revenues UNPUB 0 725,000 3,686,000
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-06 2021-08-05 2021-11-04 2022-02-22
Assets 471,416,000 432,892,000 387,008,000 408,152,000
Current Assets 465,975,000 427,554,000 381,770,000 402,773,000
Current Liabilities 15,314,000 13,347,000 19,058,000 33,326,000
Equity 450,994,000 414,488,000 362,995,000 297,677,000
Equity Attributable To Noncontrolling Interest 0 0 0 0
Equity Attributable To Parent 450,994,000 414,488,000 362,995,000 297,677,000
Liabilities 20,422,000 18,404,000 24,013,000 110,475,000
Liabilities And Equity 471,416,000 432,892,000 387,008,000 408,152,000
Noncurrent Assets 5,441,000 5,338,000 5,238,000 5,379,000
Noncurrent Liabilities 0 0 4,955,000 77,149,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-06 2021-08-05 2021-11-04 2022-02-22
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow 223,608,000 -199,562,000 -37,350,000 31,367,000
Net Cash Flow, Continuing 223,608,000 -199,562,000 -37,350,000 31,367,000
Net Cash Flow From Financing Activities 207,815,000 1,188,000 63,000 281,947,000
Net Cash Flow From Financing Activities, Continuing 207,815,000 1,188,000 63,000 281,947,000
Net Cash Flow From Investing Activities 61,996,000 -164,919,000 3,471,000 -75,953,000
Net Cash Flow From Investing Activities, Continuing 61,996,000 -164,919,000 3,471,000 -75,953,000
Net Cash Flow From Operating Activities -46,203,000 -35,831,000 -40,884,000 -174,627,000
Net Cash Flow From Operating Activities, Continuing -46,203,000 -35,831,000 -40,884,000 -174,627,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-06 2021-08-05 2021-11-04 2022-02-22
Comprehensive Income/Loss -36,042,000 -42,008,000 -56,962,000 -206,609,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Comprehensive Income/Loss Attributable To Parent -35,998,000 -42,086,000 -56,962,000 -206,609,000
Other Comprehensive Income/Loss 0 0 -56,962,000 -206,609,000
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-06 2021-08-05 2021-11-04 2022-02-22
Basic Earnings Per Share -1 -1 -1 -4
Benefits Costs and Expenses UNPUB UNPUB UNPUB UNPUB
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses UNPUB UNPUB UNPUB UNPUB
Diluted Earnings Per Share -1 -1 -1 -4
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -36,042,000 -42,008,000 -56,980,000 -206,356,000
Income/Loss From Continuing Operations Before Tax -36,042,000 -42,008,000 -56,980,000 -206,356,000
Income Tax Expense/Benefit UNPUB UNPUB UNPUB 0
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss -36,042,000 -42,008,000 -56,980,000 -206,356,000
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Net Income/Loss Attributable To Parent -36,042,000 -42,008,000 -56,980,000 -206,356,000
Net Income/Loss Available To Common Stockholders, Basic -36,042,000 -42,008,000 -56,980,000 -206,356,000
Operating Expenses 36,085,000 42,080,000 57,078,000 206,529,000
Operating Income/Loss -36,085,000 -42,080,000 -57,078,000 -206,529,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 0
Preferred Stock Dividends And Other Adjustments 0 0 0 0
Revenues 0 0 0 0
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2020-05-12 2020-08-11 2020-11-05 2021-02-16
Assets 254,392,000 231,970,000 198,013,000 298,269,000
Current Assets 253,878,000 228,035,000 194,121,000 292,826,000
Current Liabilities 12,222,000 19,281,000 21,154,000 22,602,000
Equity 241,882,000 208,923,000 173,071,000 270,621,000
Equity Attributable To Noncontrolling Interest 0 0 0 0
Equity Attributable To Parent 241,882,000 208,923,000 173,071,000 270,621,000
Liabilities 12,510,000 23,047,000 24,942,000 27,648,000
Liabilities And Equity 254,392,000 231,970,000 198,013,000 298,269,000
Noncurrent Assets 514,000 3,935,000 3,892,000 5,443,000
Noncurrent Liabilities 0 0 3,788,000 5,046,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2020-05-12 2020-08-11 2020-11-05 2021-02-16
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow 127,557,000 -19,347,000 -125,839,000 3,288,000
Net Cash Flow, Continuing 127,557,000 -19,347,000 -125,839,000 3,288,000
Net Cash Flow From Financing Activities 168,893,000 309,000 -437,000 298,145,000
Net Cash Flow From Financing Activities, Continuing 168,893,000 309,000 -437,000 298,145,000
Net Cash Flow From Investing Activities -20,326,000 6,105,000 -91,711,000 -181,824,000
Net Cash Flow From Investing Activities, Continuing -20,326,000 6,105,000 -91,711,000 -181,824,000
Net Cash Flow From Operating Activities -21,010,000 -25,761,000 -33,691,000 -113,033,000
Net Cash Flow From Operating Activities, Continuing -21,010,000 -25,761,000 -33,691,000 -113,033,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2020-05-12 2020-08-11 2020-11-05 2021-02-16
Comprehensive Income/Loss -28,013,000 -35,412,000 -38,204,000 -135,679,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Comprehensive Income/Loss Attributable To Parent -27,993,000 -35,431,000 -38,200,000 -135,679,000
Other Comprehensive Income/Loss 0 0 0 -135,679,000
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2020-05-12 2020-08-11 2020-11-05 2021-02-16
Basic Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Benefits Costs and Expenses UNPUB UNPUB UNPUB UNPUB
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses UNPUB UNPUB UNPUB UNPUB
Diluted Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -28,013,000 -35,412,000 -38,204,000 -135,678,000
Income/Loss From Continuing Operations Before Tax -28,013,000 -35,412,000 -38,204,000 -135,678,000
Income Tax Expense/Benefit UNPUB UNPUB UNPUB 0
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss -28,013,000 -35,412,000 -38,204,000 -135,678,000
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Net Income/Loss Attributable To Parent -28,013,000 -35,412,000 -38,204,000 -135,678,000
Net Income/Loss Available To Common Stockholders, Basic -28,013,000 -35,412,000 -38,204,000 -135,678,000
Operating Expenses 28,651,000 35,627,000 38,303,000 136,645,000
Operating Income/Loss -28,651,000 -35,627,000 -38,303,000 -136,645,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 0
Preferred Stock Dividends And Other Adjustments 0 0 0 0
Revenues 0 0 0 0
Calendar
16 May 2024 (Time UTC) Actual Previous Consensus
★★
11:30
United States
★
11:30
United States
5.275
★
11:30
United States
5.270
★
11:30
United States
★
11:30
United States
★★
10:30
United States
★
10:30
United States
MAY 10
70000000000.000
79000000000.000
76000000000.000
★
10:30
United States
MAY 10
★★
10:00
United States
★
09:15
United States
APR
-0.300
0.200
0.100
★★
09:15
United States
APR
-0.380
0.090
★
09:15
United States
APR
78.400
78.500
78.400
★
09:15
United States
APR
★★
08:30
United States
APR
0.500
0.100
0.400
★★
08:30
United States
APR
1440000.000
1458000.000
1480000.000
Options
Ticker
CFI
Contract Type
Exercise Style
Share Per Contract
Strike Price
Primary Exchange
Expiration Date
O:ARQT240419P00020000 OPASPS Put American 100 20 BATO 2024-04-19
O:ARQT240419P00017500 OPASPS Put American 100 17.5 BATO 2024-04-19
O:ARQT240419P00015000 OPASPS Put American 100 15 BATO 2024-04-19
O:ARQT240419P00012500 OPASPS Put American 100 12.5 BATO 2024-04-19
O:ARQT240419P00010000 OPASPS Put American 100 10 BATO 2024-04-19
O:ARQT240419P00007500 OPASPS Put American 100 7.5 BATO 2024-04-19
O:ARQT240419P00005000 OPASPS Put American 100 5 BATO 2024-04-19
O:ARQT240419P00002500 OPASPS Put American 100 2.5 BATO 2024-04-19
O:ARQT240419C00020000 OCASPS Call American 100 20 BATO 2024-04-19
O:ARQT240419C00017500 OCASPS Call American 100 17.5 BATO 2024-04-19
O:ARQT240419C00015000 OCASPS Call American 100 15 BATO 2024-04-19
O:ARQT240419C00012500 OCASPS Call American 100 12.5 BATO 2024-04-19
O:ARQT240419C00010000 OCASPS Call American 100 10 BATO 2024-04-19
O:ARQT240419C00007500 OCASPS Call American 100 7.5 BATO 2024-04-19
O:ARQT240419C00005000 OCASPS Call American 100 5 BATO 2024-04-19
O:ARQT240419C00002500 OCASPS Call American 100 2.5 BATO 2024-04-19
O:ARQT240315P00020000 OPASPS Put American 100 20 BATO 2024-03-15
O:ARQT240315P00017500 OPASPS Put American 100 17.5 BATO 2024-03-15
O:ARQT240315P00015000 OPASPS Put American 100 15 BATO 2024-03-15
O:ARQT240315P00012500 OPASPS Put American 100 12.5 BATO 2024-03-15
O:ARQT240315P00010000 OPASPS Put American 100 10 BATO 2024-03-15
O:ARQT240315P00007500 OPASPS Put American 100 7.5 BATO 2024-03-15
O:ARQT240315P00005000 OPASPS Put American 100 5 BATO 2024-03-15
O:ARQT240315P00002500 OPASPS Put American 100 2.5 BATO 2024-03-15
O:ARQT240315C00020000 OCASPS Call American 100 20 BATO 2024-03-15
O:ARQT240315C00017500 OCASPS Call American 100 17.5 BATO 2024-03-15
O:ARQT240315C00015000 OCASPS Call American 100 15 BATO 2024-03-15
O:ARQT240315C00012500 OCASPS Call American 100 12.5 BATO 2024-03-15
O:ARQT240315C00010000 OCASPS Call American 100 10 BATO 2024-03-15
O:ARQT240315C00007500 OCASPS Call American 100 7.5 BATO 2024-03-15
O:ARQT240315C00005000 OCASPS Call American 100 5 BATO 2024-03-15
O:ARQT240315C00002500 OCASPS Call American 100 2.5 BATO 2024-03-15
O:ARQT240216P00007500 OPASPS Put American 100 7.5 BATO 2024-02-16
O:ARQT240216P00005000 OPASPS Put American 100 5 BATO 2024-02-16
O:ARQT240216P00002500 OPASPS Put American 100 2.5 BATO 2024-02-16
O:ARQT240216C00007500 OCASPS Call American 100 7.5 BATO 2024-02-16
O:ARQT240216C00005000 OCASPS Call American 100 5 BATO 2024-02-16
O:ARQT240216C00002500 OCASPS Call American 100 2.5 BATO 2024-02-16
O:ARQT240119P00007500 OPASPS Put American 100 7.5 BATO 2024-01-19
O:ARQT240119P00005000 OPASPS Put American 100 5 BATO 2024-01-19
O:ARQT240119P00002500 OPASPS Put American 100 2.5 BATO 2024-01-19
O:ARQT240119C00007500 OCASPS Call American 100 7.5 BATO 2024-01-19
O:ARQT240119C00005000 OCASPS Call American 100 5 BATO 2024-01-19
O:ARQT240119C00002500 OCASPS Call American 100 2.5 BATO 2024-01-19
O:ARQT231215P00020000 OPASPS Put American 100 20 BATO 2023-12-15
O:ARQT231215P00017500 OPASPS Put American 100 17.5 BATO 2023-12-15
O:ARQT231215P00015000 OPASPS Put American 100 15 BATO 2023-12-15
O:ARQT231215P00012500 OPASPS Put American 100 12.5 BATO 2023-12-15
O:ARQT231215P00010000 OPASPS Put American 100 10 BATO 2023-12-15
O:ARQT231215P00007500 OPASPS Put American 100 7.5 BATO 2023-12-15
O:ARQT231215P00005000 OPASPS Put American 100 5 BATO 2023-12-15
O:ARQT231215P00002500 OPASPS Put American 100 2.5 BATO 2023-12-15
O:ARQT231215C00025000 OCASPS Call American 100 25 BATO 2023-12-15
O:ARQT231215C00022500 OCASPS Call American 100 22.5 BATO 2023-12-15
O:ARQT231215C00020000 OCASPS Call American 100 20 BATO 2023-12-15
O:ARQT231215C00017500 OCASPS Call American 100 17.5 BATO 2023-12-15
O:ARQT231215C00015000 OCASPS Call American 100 15 BATO 2023-12-15
O:ARQT231215C00012500 OCASPS Call American 100 12.5 BATO 2023-12-15
O:ARQT231215C00010000 OCASPS Call American 100 10 BATO 2023-12-15
O:ARQT231215C00007500 OCASPS Call American 100 7.5 BATO 2023-12-15
O:ARQT231215C00005000 OCASPS Call American 100 5 BATO 2023-12-15
O:ARQT231215C00002500 OCASPS Call American 100 2.5 BATO 2023-12-15
O:ARQT231215P00025000 OPASPS Put American 100 25 BATO 2023-12-15
O:ARQT231215P00022500 OPASPS Put American 100 22.5 BATO 2023-12-15
O:ARQT231117P00015000 OPASPS Put American 100 15 BATO 2023-11-17
O:ARQT231117P00012500 OPASPS Put American 100 12.5 BATO 2023-11-17
O:ARQT231117P00010000 OPASPS Put American 100 10 BATO 2023-11-17
O:ARQT231117P00007500 OPASPS Put American 100 7.5 BATO 2023-11-17
O:ARQT231117P00005000 OPASPS Put American 100 5 BATO 2023-11-17
O:ARQT231117P00002500 OPASPS Put American 100 2.5 BATO 2023-11-17
O:ARQT231117C00015000 OCASPS Call American 100 15 BATO 2023-11-17
O:ARQT231117C00012500 OCASPS Call American 100 12.5 BATO 2023-11-17
O:ARQT231117C00010000 OCASPS Call American 100 10 BATO 2023-11-17
O:ARQT231117C00007500 OCASPS Call American 100 7.5 BATO 2023-11-17
O:ARQT231117C00005000 OCASPS Call American 100 5 BATO 2023-11-17
O:ARQT231117C00002500 OCASPS Call American 100 2.5 BATO 2023-11-17
O:ARQT231020P00015000 OPASPS Put American 100 15 BATO 2023-10-20
O:ARQT231020P00012500 OPASPS Put American 100 12.5 BATO 2023-10-20
O:ARQT231020P00010000 OPASPS Put American 100 10 BATO 2023-10-20
O:ARQT231020P00007500 OPASPS Put American 100 7.5 BATO 2023-10-20
O:ARQT231020P00005000 OPASPS Put American 100 5 BATO 2023-10-20
O:ARQT231020P00002500 OPASPS Put American 100 2.5 BATO 2023-10-20
O:ARQT231020C00015000 OCASPS Call American 100 15 BATO 2023-10-20
O:ARQT231020C00012500 OCASPS Call American 100 12.5 BATO 2023-10-20
O:ARQT231020C00010000 OCASPS Call American 100 10 BATO 2023-10-20
O:ARQT231020C00007500 OCASPS Call American 100 7.5 BATO 2023-10-20
O:ARQT231020C00005000 OCASPS Call American 100 5 BATO 2023-10-20
O:ARQT231020C00002500 OCASPS Call American 100 2.5 BATO 2023-10-20
O:ARQT230915P00030000 OPASPS Put American 100 30 BATO 2023-09-15
O:ARQT230915P00025000 OPASPS Put American 100 25 BATO 2023-09-15
O:ARQT230915P00022500 OPASPS Put American 100 22.5 BATO 2023-09-15
O:ARQT230915P00020000 OPASPS Put American 100 20 BATO 2023-09-15
O:ARQT230915P00017500 OPASPS Put American 100 17.5 BATO 2023-09-15
O:ARQT230915P00015000 OPASPS Put American 100 15 BATO 2023-09-15
O:ARQT230915P00012500 OPASPS Put American 100 12.5 BATO 2023-09-15
O:ARQT230915P00010000 OPASPS Put American 100 10 BATO 2023-09-15
O:ARQT230915P00007500 OPASPS Put American 100 7.5 BATO 2023-09-15
O:ARQT230915P00005000 OPASPS Put American 100 5 BATO 2023-09-15
O:ARQT230915P00002500 OPASPS Put American 100 2.5 BATO 2023-09-15
O:ARQT230915C00030000 OCASPS Call American 100 30 BATO 2023-09-15
O:ARQT230915C00025000 OCASPS Call American 100 25 BATO 2023-09-15
O:ARQT230915C00022500 OCASPS Call American 100 22.5 BATO 2023-09-15
O:ARQT230915C00020000 OCASPS Call American 100 20 BATO 2023-09-15
O:ARQT230915C00017500 OCASPS Call American 100 17.5 BATO 2023-09-15
O:ARQT230915C00015000 OCASPS Call American 100 15 BATO 2023-09-15
O:ARQT230915C00012500 OCASPS Call American 100 12.5 BATO 2023-09-15
O:ARQT230915C00010000 OCASPS Call American 100 10 BATO 2023-09-15
O:ARQT230915C00007500 OCASPS Call American 100 7.5 BATO 2023-09-15
O:ARQT230915C00005000 OCASPS Call American 100 5 BATO 2023-09-15
O:ARQT230915C00002500 OCASPS Call American 100 2.5 BATO 2023-09-15
O:ARQT230818P00020000 OPASPS Put American 100 20 BATO 2023-08-18
O:ARQT230818P00017500 OPASPS Put American 100 17.5 BATO 2023-08-18
O:ARQT230818P00015000 OPASPS Put American 100 15 BATO 2023-08-18
O:ARQT230818P00012500 OPASPS Put American 100 12.5 BATO 2023-08-18
O:ARQT230818P00010000 OPASPS Put American 100 10 BATO 2023-08-18
O:ARQT230818P00007500 OPASPS Put American 100 7.5 BATO 2023-08-18
O:ARQT230818P00005000 OPASPS Put American 100 5 BATO 2023-08-18
O:ARQT230818P00002500 OPASPS Put American 100 2.5 BATO 2023-08-18
O:ARQT230818C00020000 OCASPS Call American 100 20 BATO 2023-08-18
O:ARQT230818C00017500 OCASPS Call American 100 17.5 BATO 2023-08-18
O:ARQT230818C00015000 OCASPS Call American 100 15 BATO 2023-08-18
O:ARQT230818C00012500 OCASPS Call American 100 12.5 BATO 2023-08-18
O:ARQT230818C00010000 OCASPS Call American 100 10 BATO 2023-08-18
O:ARQT230818C00007500 OCASPS Call American 100 7.5 BATO 2023-08-18
O:ARQT230818C00005000 OCASPS Call American 100 5 BATO 2023-08-18
O:ARQT230818C00002500 OCASPS Call American 100 2.5 BATO 2023-08-18
News Stream
Stocks Earnings Releases and Operating Results
Arcutis Announces First Quarter 2024 Financial Results and Provides Business Update
Arcutis today reported financial results for the quarter ended March 31, 2024, and provided a business update.
GlobeNewswire Inc. • 1d ago
Stocks Changes in company's own shares
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WESTLAKE VILLAGE, Calif., May 03, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 160,500 restricted stock units of Arcutis’ common stock as well as options to purchase an aggregate of 117,000 shares of Arcutis’ common stock to 13 newly hired employees. These awards were approved by the Compensation Committee of Arcutis’ Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of May 1, 2024, as an inducement material to the new employees entering into employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4).
GlobeNewswire Inc. • 1w ago
Calendar Calendar of Events
Arcutis to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
Arcutis today announced that it will report first quarter 2024 financial results and provide a business update on Tuesday, May 14, 2024.
GlobeNewswire Inc. • 2w ago
Analyst Analyst Ratings
Evaluating Arcutis Biotherapeutics: Insights From 5 Financial Analysts
Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on Arcutis Biotherapeutics (NASDAQ:ARQT) in the last three months. The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 0 1 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 3 0 1 0 0 3M Ago 0 0 0 0 0 Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $15.2, with a high estimate of $17.00 and a low estimate of $11.00. Marking an increase of 60.0%, the current average surpasses the previous average price target of $9.50. Understanding Analyst Ratings: A Comprehensive Breakdown The standing of Arcutis Biotherapeutics among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Serge Belanger Needham Maintains Buy $16.00 - Jonathan Block Goldman Sachs Raises Neutral $11.00 $6.00 Uy Ear Mizuho Raises Buy $17.00 $16.00 Serge Belanger Needham Raises Buy $16.00 $8.00 Uy Ear Mizuho Raises Buy $16.00 $8.00 Key Insights: Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Arcutis Biotherapeutics. This offers insight into analysts' perspectives on the current state of ...Full story available on Benzinga.com
Benzinga • 1mo ago
Management Directors and Officers
Arcutis Appoints David Topper as Chief Financial Officer
Arcutis today announced that David Topper has been appointed Chief Financial Officer effective April 10, 2024.
GlobeNewswire Inc. • 1mo ago
Stocks Changes in company's own shares
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WESTLAKE VILLAGE, Calif., April 05, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 58,500 restricted stock units of Arcutis’ common stock to four newly hired employees. These awards were approved by the Compensation Committee of Arcutis’ Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of April 1, 2024, as an inducement material to the new employees entering into employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4).
GlobeNewswire Inc. • 1mo ago
News News
Arcutis Biotherapeutics, Inc. (ARQT) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Arcutis Biotherapeutics, Inc. (ARQT) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Zacks Investment Research • 1mo ago
News News
Wall Street Analysts See a 54.78% Upside in Arcutis Biotherapeutics, Inc. (ARQT): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 54.8% in Arcutis Biotherapeutics, Inc. (ARQT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks Investment Research • 1mo ago
News Clinical Study
Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual Meeting
Investigational roflumilast cream 0.05% met the primary endpoint and all secondary endpoints, showing significant improvement
GlobeNewswire Inc. • 2mo ago
Stocks Research Analysis and Reports
New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction
These findings are the first to characterize the unique molecular profile of seborrheic dermatitis
GlobeNewswire Inc. • 2mo ago
See All
Related
Latest

Contactez-nous dès aujourd'hui pour découvrir comment notre solution peut vous aider à tirer parti de la puissance des données.

CONTACTER UN EXPERT